Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity
Top Cited Papers
- 4 February 2007
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 13 (2), 189-197
- https://doi.org/10.1038/nm1545
Abstract
Hyperaldosteronism is associated with impaired vascular reactivity; however, the mechanisms by which aldosterone promotes endothelial dysfunction remain unknown. Glucose-6-phosphate dehydrogenase (G6PD) modulates vascular function by limiting oxidant stress to preserve bioavailable nitric oxide (NO•). Here we show that aldosterone (10−9–;10−7 mol/l) decreased endothelial G6PD expression and activity in vitro, resulting in increased oxidant stress and decreased NO• levels—similar to what is observed in G6PD-deficient endothelial cells. Aldosterone decreased G6PD expression by increasing expression of the cyclic AMP−response element modulator (CREM) to inhibit cyclic AMP−response element binding protein (CREB)-mediated G6PD transcription. In vivo, infusion of aldosterone decreased vascular G6PD expression and impaired vascular reactivity. These effects were abrogated by spironolactone or vascular gene transfer of G6pd. These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity.Keywords
This publication has 50 references indexed in Scilit:
- Molecular Mechanism of the Inhibitory Effect of Aldosterone on Endothelial NO Synthase ActivityHypertension, 2006
- Endothelial dysfunction in the streptozotocin‐induced diabetic apoE‐deficient mouseBritish Journal of Pharmacology, 2005
- Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatmentHeart, 2004
- Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapyThe American Journal of Cardiology, 2004
- Aldosterone-induced vasculopathyMolecular and Cellular Endocrinology, 2004
- Glucose-6-phosphate Dehydrogenase Modulates Vascular Endothelial Growth Factor-mediated AngiogenesisJournal of Biological Chemistry, 2003
- The A376G(A+) variant of the glucose-6-phosphate dehydrogenase gene is associated with endothelial dysfunction in African AmericansJournal of the American College of Cardiology, 2003
- Glucose-6-Phosphate Dehydrogenase Overexpression Decreases Endothelial Cell Oxidant Stress and Increases Bioavailable Nitric OxideArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Glucose‐6‐phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailabilityThe FASEB Journal, 2001
- Effects of aldosterone on blood pressure and glucose-6-phosphate dehydrogenase activity of heart muscleCanadian Journal of Physiology and Pharmacology, 1969